Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 26, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

October 31, 2019

Conditions
Salivary Gland Carcinoma
Interventions
DRUG

pazopanib

treatment will be given until progression or unacceptable toxicity .

Trial Locations (15)

94

Gustave Roussy, Villejuif

21079

Centre Georges François Leclerc, Dijon

33075

CHU Bordeaux, Bordeaux

34298

Centre Val d'Aurelle Paul Lamarque, Montpellier

35042

Centre Eugène Marquis, Rennes

48805

Institut Cancérologie de l'Ouest, Saint-Herblain

49933

Institut de Cancérologie de l'Ouest Paul Papin, Angers

59020

Centre Oscar Lambret, Lille

63011

Centre Jean Perrin, Clermont-Ferrand

67065

Centre Paul Strauss, Strasbourg

69373

Centre Léon Bérard, Lyon

75231

Institut Curie, Paris

75674

Centre Hospitalier St Joseph, Paris

92210

Institut Curie site St Cloud, Saint-Cloud

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

UNICANCER

OTHER

NCT02393820 - Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma | Biotech Hunter | Biotech Hunter